Xcout IntelGridAI Technologies Corp. competitors & alternatives
The 7 closest competitors and alternatives to GridAI Technologies Corp. among ai/ml companies — ranked by similarity to what GridAI Technologies Corp. actually does, not by market-cap band.
Subscribe to see GridAI Technologies Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About GridAI Technologies Corp.
GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.
GridAI Technologies Corp. at a glance
GridAI Technologies Corp. is an ai/ml company headquartered in Edinburgh, United States. It is publicly listed (GRDX) with a market capitalisation of $29.7M. Xcout tracks 17 named people at GridAI Technologies Corp., including Jason David Sawyer (Chief Executive Officer & Director).
GridAI Technologies Corp. leadership
- Jason David SawyerChief Executive Officer & Director
- Marshall ChapinChief Executive Officer of GridAI, Inc
- Anna SkowronInterim Chief Financial Officer
- Anna SkowronExecutive Officer
- Jason SawyerExecutive Officer
- Chaitan Phd KhoslaDirector
11 more named people on record for GridAI Technologies Corp., with roles, board committees and tenure — see the full roster →
Top 7 GridAI Technologies Corp. competitors
Ranked by semantic similarity — how close each company is to GridAI Technologies Corp. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar ai/ml company
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Similar ai/ml company
BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.
Similar ai/ml company
Vocodia Holdings Corp. specializes in crafting advanced conversational artificial intelligence platforms designed for sales and customer engagement. Its flagship offering, DISA, is a sophisticated human-like AI technology capable of managing every step of the dialogue-based sales journey, serving both corporate clients (B2B) and individual customers (B2C). Beyond its core AI solutions, the firm also delivers information technology services. Established in 2020, the company operates out of Boca Raton, Florida.
Artificial Intelligence
Based in Jupiter, Florida, and established in 2009, Global AI, Inc. primarily engages in the exploration, development, and provision of artificial intelligence (AI)-powered products, solutions, and services throughout the United States. The firm also offers specialized consulting services. Its extensive client base includes institutional investors, a variety of financial and non-financial corporations, government agencies, and multilateral international organizations. Having previously been known as Wall Street Media Co., Inc., the company officially adopted its current name, Global AI, Inc., in October 2023. It operates as a subsidiary of Ingenious Investment Ag.
Artificial Intelligence
Manas AI is an AI-native biopharmaceutical company headquartered in New York, NY. The company combines pioneering artificial intelligence technology with chemistry, physics, and biology to transform drug discovery.
Similar ai/ml company
Core AI Holdings, Inc. operates as an AI technology and infrastructure company. The company focuses on identifying, developing, and scaling AI-driven businesses that leverage technologies to address various market opportunities. It is also involved in the AI-driven mobile game development and publishing business. The company is based in Miami, Florida.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of GridAI Technologies Corp. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for GridAI Technologies Corp.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →